Evogene (EVGN) Director Leon Recanati Buys 460,000 Shares

What Happened Leon Recanati, a director of Evogene Ltd. (EVGN), purchased 460,000 shares of Evogene common stock on August 11, 2026, at $0.64 per share, for a total cash outlay of approximately $292,100. This was a direct purchase (transaction code P), which is a buy and is generally considered more informative to investors than routine sales.

Key Details

• Transaction date and price: Aug 11, 2026 — 460,000 shares at $0.64 per share.
• Total transaction value: ≈ $292,100.
• Filing date: Form 4 filed Aug 13, 2026 (timely filing; within the SEC’s reporting window).
• Shares owned after transaction: Not specified in the Form 4.
• Footnotes of record:
  • F1: Indicates a row in the filing was included for informational purposes and reported no transaction for that row.
  • F2: Notes certain options vest quarterly and fully vest one year after an Aug 18, 2025 grant (appears to relate to option holdings disclosed elsewhere in the filing).
• Remarks: Exhibit 24.1 (Power of Attorney) included with the filing.

Context This filing reports a straightforward open-market purchase of common stock (P = Purchase), not a derivative exercise or gift. Purchases by insiders can be read as a positive signal by some investors, but the Form 4 provides only transaction facts — it does not state the insider’s motivation.